Counteracting neuroinflammation in experimental Parkinson’s disease favors recovery of function: effects of Er-NPCs administration
Autor: | Federica Rey, Zuzana Gombalova, Anna Maria Di Giulio, T. Giallongo, Stephana Carelli, Massimiliano Mazza, Maria Carlotta F. Gorio |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine Parkinson's disease Nigrostriatal pathway Striatum Pharmacology lcsh:RC346-429 Mice chemistry.chemical_compound 0302 clinical medicine Neural Stem Cells Neuroinflammation Adult stem cells Microglia General Neuroscience MPTP Dopaminergic Smell medicine.anatomical_structure Neurology 1-Methyl-4-phenyl-1 2 3 6-tetrahydropyridine Regenerative medicine Cytokines Encephalitis Tyrosine 3-Monooxygenase Green Fluorescent Proteins Neural stem cells transplantation Immunology 03 medical and health sciences Cellular and Molecular Neuroscience Parkinsonian Disorders medicine Animals Muscle Strength Erythropoietin lcsh:Neurology. Diseases of the nervous system Dopamine Plasma Membrane Transport Proteins business.industry Research Recovery of Function medicine.disease Coculture Techniques Corpus Striatum Mice Inbred C57BL Transplantation Disease Models Animal 030104 developmental biology chemistry Parkinson’s disease business 030217 neurology & neurosurgery |
Zdroj: | Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-17 (2018) Journal of Neuroinflammation |
ISSN: | 1742-2094 |
DOI: | 10.1186/s12974-018-1375-2 |
Popis: | Background Parkinson’s disease (PD) is the second most common neurodegenerative disease, presenting with midbrain dopaminergic neurons degeneration. A number of studies suggest that microglial activation may have a role in PD. It has emerged that inflammation-derived oxidative stress and cytokine-dependent toxicity may contribute to nigrostriatal pathway degeneration and exacerbate the progression of the disease in patients with idiopathic PD. Cell therapies have long been considered a feasible regenerative approach to compensate for the loss of specific cell populations such as the one that occurs in PD. We recently demonstrated that erythropoietin-releasing neural precursors cells (Er-NPCs) administered to MPTP-intoxicated animals survive after transplantation in the recipient’s damaged brain, differentiate, and rescue degenerating striatal dopaminergic neurons. Here, we aimed to investigate the potential anti-inflammatory actions of Er-NPCs infused in an MPTP experimental model of PD. Methods The degeneration of dopaminergic neurons was caused by MPTP administration in C57BL/6 male mice. 2.5 × 105 GFP-labeled Er-NPCs were administered by stereotaxic injection unilaterally in the left striatum. Functional recovery was assessed by two independent behavioral tests. Neuroinflammation was investigated measuring the mRNAs levels of pro-inflammatory and anti-inflammatory cytokines, and immunohistochemistry studies were performed to evaluate markers of inflammation and the potential rescue of tyrosine hydroxylase (TH) projections in the striatum of recipient mice. Results Er-NPC administration promoted a rapid anti-inflammatory effect that was already evident 24 h after transplant with a decrease of pro-inflammatory and increase of anti-inflammatory cytokines mRNA expression levels. This effect was maintained until the end of the observational period, 2 weeks post-transplant. Here, we show that Er-NPCs transplant reduces macrophage infiltration, directly counteracting the M1-like pro-inflammatory response of murine-activated microglia, which corresponds to the decrease of CD68 and CD86 markers, and induces M2-like pro-regeneration traits, as indicated by the increase of CD206 and IL-10 expression. Moreover, we also show that this activity is mediated by Er-NPCs-derived erythropoietin (EPO) since the co-injection of cells with anti-EPO antibodies neutralizes the anti-inflammatory effect of the Er-NPCs treatment. Conclusion This study shows the anti-inflammatory actions exerted by Er-NPCs, and we suggest that these cells may represent good candidates for cellular therapy to counteract neuroinflammation in neurodegenerative disorders. Electronic supplementary material The online version of this article (10.1186/s12974-018-1375-2) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |